F8 and hemophilia A: Other recent studies have obtained F8c-HA hiPSCs with prominent levels of FVIII activity by CRISPR/Cas9 editing and cultured liver organoids with 3D structures and demonstrated their therapeutic efficacy in animals with haemophilia A [104].